Pharmaceuticals
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
SHANGHAI, June 26, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site (Phase I) has been recognized as the Popula...
Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa
A new era of personalized gene therapy for Leukemia patients in Egypt, Saudi Arabia, and beyond. SUZHOU, China and CAIRO, June 26, 2025 /PRNewswire/ -- Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, andEVA Pharma, one of the leading pharmaceutical compan...
Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia
SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals
BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
* Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has ...
LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success
ANDERNACH, Germany and MONTREAL, June 25, 2025 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to pr...
Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today
TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr.Benny T. Hu. The company delivered updates on its ongoing drug development programs, outl...
QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA
BRISBANE, Australia, June 25, 2025 /PRNewswire/ -- QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data * Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced S...
TVM Capital Healthcare Appoints Dr. Su-Lin Chong in Malaysia as Investment Committee Member and Operating Partner
SINGAPORE, June 25, 2025 /PRNewswire/ -- TVM Capital Healthcare, a leading international healthcare private equity firm and operator focused on emerging markets, announces the appointment of Dr. Su-Lin Chong as Operating Partner and Investment Committee member. Based in Kuala Lumpur, Dr. Chong br...
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population
NEW YORK, June 24, 2025 /PRNewswire/ -- Klotho Neuroscience, Inc. (NASDAQ: KLTO ), a US-based biogenetics company developing cell and gene- based treatments to address neurological conditions, including ALS, Alzheimer's Disease (AD) and Parkinson's Disease (PD), has announced that it is partnering...
BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
* Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individuals * Preclinical data for BGM1812 supports further development as next-generation amy...
IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that results from an ...
XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform
CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory...
Connecting Care with Clicks 2025 Draws Full House of Healthcare Leaders to Kuala Lumpur for One-Day Innovation Summit
KUALA LUMPUR, Malaysia, June 23, 2025 /PRNewswire/ -- Healthcare professionals, policy leaders, and digital health innovators gathered forConnecting Care with Clicks 2025 (CCC 2025), a one-day summit at InterContinental Kuala Lumpur, spotlighting key trends shaping the future of healthcare in Sou...
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collabora...
Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)
SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that theSpecifications for Antimicro...
Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 21, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
* In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weig...
Everest Medicines Announces Successful Release of First Clinical Batch of Tumor-Associated Antigen Vaccine EVM14 at Jiashan Manufacturing Site
SHANGHAI, June 20, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the successful release of the first ...
The Department of Health - Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi
Reinforcing Abu Dhabi's position as a global life science hub
ABU DHABI, UAE, June 20, 2025 /PRNewswire/ -- During BIO International
Convention in Boston USA, theDepartment of Health – Abu Dhabi
Week's Top Stories
Most Reposted
BoomerangFX Launches ChatGPT AI Search Advertising for Aesthetic, Wellness and Private-Pay Healthcare Practices, Powered by AUVIA™ AI Clinic Co-Pilot
[Picked up by 1315 media titles]
2026-11-17 23:03Manulife announces Subordinated Debenture issue
[Picked up by 1205 media titles]
2026-11-17 06:45vVardis Raises $175 Million Ahead of NYSE IPO: NYSE Content Update
[Picked up by 1188 media titles]
2026-11-13 22:11The NYSE Welcomes vVARDIS as a Publicly Listed Company
[Picked up by 1176 media titles]
2026-11-14 13:23Cision Introduces AI-Powered Cision Intelligence to Help Brands See More and Act with Confidence
[Picked up by 1172 media titles]
2026-11-12 23:00